Dignitana

Continued progress with increasing activity and awareness

Financial highlights Q1 2024

• Net Sales amounted to 21.2 MSEK (21.5), a decrease of 2 percent over the same quarter in 2023.
• Operating Result amounted to -5.0 MSEK (-3.5).
• Net Result after financial items amounted to -5.1 MSEK (-3.9).
• EBITDA for the First Quarter is negative at -1.1 MSEK (0.2).
• Earnings per share were -0.07 SEK (-0.06).
• Cash Balance amounted at 2.8 MSEK (11.7).
• Average Daily Treatment Revenue (ADTR)* was 241 TSEK (242) in the quarter.

Business highlights during the period

• Dignitana held an Extraordinary General Meeting to resolve on the rights issue and to obtain a bridge loan.
• Dignitana convened Training Academy bringing distributors to Lund Headquarters.
• DigniCap Delta received market approval in Japan with Konica Minolta as Dignitana’s Distribution partner.
• Dignitana signed OncoMedical for distribution in Switzerland and Liechtenstein.
• Preliminary result of DigniCap Delta study in Uruguay demonstrated very high efficacy compared to previous studies.
• DigniCap Delta study is underway in Brindisi, Italy.
• Dignitana nominated for Inaugural Texas Impact Enterprise Awards.
• Dignitana invited to address MedTech innovation on a panel at SXSW® conference in Texas.

Business highlights after the period

• Dignitana Rights Issue was fully subscribed at 19.1 MSEK before issue cost.
• Fredrik Jonsson appointed as CEO beginning 1 May 2024 following resignation of Caterina Lowenadler.
• Dignitana signed an exclusivity agreement with Konica Minolta as distributor for DigniCap in Japan.
• Dignitana exhibited at the Oncology Nursing Congress in Washington, DC

Key Figures

*ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

All financial reports are available at www.dignitana.com/investor-relations/financial-reports/